Activating oncogenic mutations of receptor tyrosine kinases (RTKs) have been reported in several types of cancers. In many cases, genomic rearrangements lead to the fusion of unrelated genes to the DNA coding for the kinase domain of RTKs. All RTK-derived fusion proteins reported so far display oligomerization sequences within the 5 fusion partners that are responsible for oncogenic activation. Here, we report a mechanism by which an altered RTK gains oncogenic potential in a glioblastoma cell line. A microdeletion on 6q21 results in the fusion of FIG, a gene coding 
Activating oncogenic mutations of receptor tyrosine kinases (RTKs) have been reported in several types of cancers. In many cases, genomic rearrangements lead to the fusion of unrelated genes to the DNA coding for the kinase domain of RTKs. All RTK-derived fusion proteins reported so far display oligomerization sequences within the 5 fusion partners that are responsible for oncogenic activation. Here, we report a mechanism by which an altered RTK gains oncogenic potential in a glioblastoma cell line. R eceptor tyrosine kinases (RTKs) function as key regulators of normal cellular physiology and are also involved in the development and progression of human cancers. Oncogenic activations of RTKs are often the result of genetic lesions such as point mutations, overexpression, and structural genomic rearrangements (for recent reviews see refs. 1 and 2). Of the 58 known human RTKs, 8 have been shown to be involved in in-frame fusion events where unrelated sequences fused 5Ј to the sequence coding for the tyrosine kinase domain lead to the production of a constitutively activated kinase. The vast majority of such events has been characterized in hematological malignancies and is the result of chromosomal translocations or inversions (1) . In all cases reported, the resulting fusion protein displays a constitutive tyrosine kinase activity attributable to dimerization domains found within the amino-terminal fusion partner. By creating such forced dimers, the catalytic kinase domains are thus juxtaposed in an optimal orientation for transphosphorylation somewhat similar to that of ligand-induced receptor dimers.
Generally, RTK-derived oncofusion proteins have no other mutations within the kinase moiety, suggesting an activation of signal transduction pathways qualitatively identical to their full-length receptor counterparts. However, these fusion kinases do not localize to the plasma membrane but are instead found within the cytosol. The possibility that the fusion protein can signal by a mechanism different from that of its normal RTK counterpart raises the following basic question: can subcellular localization of an oncogene product be an important determinant for neoplastic transformation?
The transmembrane RTK ROS shows a specific profile of expression restricted primarily to distinct epithelial cells during embryonic development (3) (4) (5) (6) . ROS is a 260-kDa glycoprotein receptor for which no ligand is known. ROS was discovered concomitantly through genomic DNA transfer transformation experiments (7) and as the oncogenic agent in the avian sarcoma retrovirus UR2 (8) . These experiments showed that deregulated ROS expression can result in cellular transformation. Interestingly, ectopic expression of c-Ros has been reported in meningiomas and astrocytomas, suggesting a possible role for ROS in these CNS malignancies (9) (10) (11) . However, to this date, naturally occurring activating mutations of ROS have never been reported in mammalian cells.
We have recently identified a gene called FIG that encodes a protein that peripherally associates with the Golgi apparatus and likely plays a role in Golgi function (12) . The transcript of this gene has been reported as a 5Ј fusion partner to the RTK ROS in the U118MG glioblastoma cell line (13 
Materials and Methods
Antibodies. Production and characterization of the rabbit polyclonal FIG antiserum has been described elsewhere (12) . The following antibodies were obtained from commercial sources: anti-c-Myc epitope monoclonal antibody 9E10 (Santa Cruz Biotechnology), anti-phosphotyrosine mouse monoclonal antibody PY20 (Transduction Laboratories), and anti-␤-COP rabbit polyclonal antibody (Affinity BioReagents, Golden, CO). (14) and transfected into Phoenix cells (Gary Nolan, Stanford University, Stanford, CA). Helper-free retroviruses were harvested 3-5 days after transfection and used to infect Rat1 cells as described (15) . Monoclonal cell lines were isolated by selecting individual G418-resistant colonies.
Transformation Assays. Equal numbers of cells (10 4 ) from each individual clone were plated in triplicate onto 60-mm dishes, and viable cells were counted at 2-day intervals for 8 days by using trypan blue exclusion and a hemocytometer. The saturation densities were determined from the plateau phase of growth, which occurred at 8 days after seeding. Immunofluorescence. Phosphopeptide mapping was carried out essentially according to previously published methods (17) . Protein preparations were obtained as described (12) . Protein extracts and immunoprecipitates were separated by SDS͞PAGE and electrotransferred to Immobilon P membrane (Millipore) according to the manufacturer's directions. Western blot analyses were performed with the indicated primary antibodies at dilution typically ranging from 1:500 to 1:1,000 and detected by enhanced chemiluminescence (ECL) (Renaissance, NENDuPont). In vitro kinase assays were performed as described elsewhere (18) . Immunocytochemistry was performed according to published methods (12) with the following antibody dilutions: 9E10 1:1,000, anti-␤-COP 1:500. These antibodies were subsequently incubated with CY3-conjugated goat anti-mouse IgG (1:1,000) and FITC-conjugated goat anti-rabbit IgG (1:200).
Density Gradient Ultracentrifugation and Subcellular Fractionation.
Cell lysates from Cos-1 cells transiently expressing FIG-ROS proteins prepared in CSK buffer (100 mM KCl͞10 mM Pipes [piperazine-N,NЈ-bis(2-ethanesulfonic acid), pH 7.0]͞0.5% Nonidet P-40͞300 mM sucrose͞3 mM MgCl 2 ) supplemented with 10 mM iodoacetamide and protease inhibitors were layered over 4.5-ml gradients of 5-20% sucrose containing 100 mM NaCl, 20 mM Tris⅐HCl (pH 7.5), and 0.1% Nonidet P-40. Gradients were centrifuged at 38,000 rpm in a Beckman SW55 rotor for 16 h at 4°C. Fractions (250 l) were collected from the bottom of the gradient by dripping and assayed for the presence of p109 by Western blot analysis. Subcellular fractionation was performed with lysates from retrovirus-infected Rat1 clones according to Graham and Rickwood (19) . Table 1) . Histopathology of the tumors revealed that they are malignant fibrosarcomas (data not shown). (Fig. 6 , which is published as supporting information on the PNAS web site), we focused our attention on four (Y554, Y623, Y805, and Y865) because they simultaneously conform to the profile of phosphorylation site residue preferences of tyrosine kinases (21) and represent potential SH2 and PTB domain recognition binding sites (22) (23) (24) . We mutated each of these four tyrosine residues individually to phenylalanine by site-directed mutagenesis and conducted a series of phosphopeptide mapping experiments on wild-type and single tyrosine residue-mutated FIG-ROS variants as described in Materials and Methods. None of the tyrosine mutants showed decreased kinase activity in vitro (data not shown). By comparing the tryptic phosphopeptide maps of the mutants to each other and to nonmutated FIG-ROS, we found that the tyrosine residues Y805 and Y865 are the major autophosphorylation sites of FIG-ROS (Fig. 6) . determined by Western blot analysis of cell extracts is comparable to those of unmodified wild- type FIG-ROS (Fig. 2 A) (Fig. 3) . Both endogenous p59 FIG and transfected p109 FIG-ROS products are found distributed over a limited number of gradient fractions with peaks corresponding to 60 and 110 kDa, respectively. In both cases, the observed peak sizes correspond to those of monomers.
FIG-ROS Oncogenic Activation Requires Targeting to the Golgi Appa-
ratus. The presence of unrelated sequences within several RTK fusion proteins has proven to play the determinant role in the constitutive activation of the kinase domain. For many fusion RTKs, oncogenic initiation is dictated by these 5Ј fusion sequences (18, (29) (30) (31) (32) (33) . We have demonstrated that FIG sequences do not convey homodimerizing properties to FIG-ROS (Fig. 3) . However, the second coiled-coil domain of In the transformation assays in which it was tested, the ⌬coil  FIG-ROS variant failed to elicit cellular transformation (Fig. 2) . (Fig. 4) . The staining pattern of FIG-ROS in these cells was compared with that of the Golgi marker ␤-COP. Wild-type (Fig.  4 A-C) , kinase-inactive (Fig. 4 D-F) , and the double autophosphorylation-site mutant Y805,865F (Fig. 4 J-L) FIG-ROS proteins all localize to the Golgi apparatus and colocalize with ␤-COP. However, the ⌬coil FIG-ROS isoform (Fig. 4 G-I) does not target to the Golgi apparatus but rather is found dispersed throughout the cytoplasm. We confirmed this release of Golgi membrane association by cellular fractionation. The failure of the ⌬coil FIG-ROS mutant to elicit a cellular transformation response is not due to an inability to display constitutive kinase activity. To control for the integrity of its kinase activity, we performed a series of in vitro kinase assays to test for its ability to self-phosphorylate. 
Discussion
The observations presented here demonstrate that the mode of FIG-ROS activation is different from that of other receptorderived tyrosine kinase fusion proteins. The critical requirement for Golgi targeting by the second coiled-coil domain to convey cellular transformation indicates that signaling pathways required for transformation can be initiated by a tyrosine kinase when localized at Golgi membranes. The ability displayed by FIG-ROS to localize to the Golgi apparatus and to exert an oncogenic activity demonstrates the occurrence of a transforming event in which signaling originates from that subcellular location.
Our Thus an important point to address is how, if at all, mislocalized fusion proteins induce plasma membrane-derived signaling pathways in a manner similar to that of their full-length receptor counterparts. Only recently have examples of such comparison been addressed. The MET receptor and its oncogenic variant TPR-MET appear to signal through the same pathways, using an identical set of signaling molecules (37) . The biological activity of TFG-NTRK1 seems to mirror the signaling patterns of NTRK1 (25) . On the other hand, FOP-FGFR1 signaling is much different from FGFR1 itself (38) . Similarly, Tel-PDGFR␤ and PDGFR␤ signal differently (39) and Hip-PDGFR␤ transforms through different pathways than native PDGFR␤ (32) .
Ligand-mediated stimulation of artificial chimeric ROS receptors results in the phosphorylation and activation of the insulin receptor substrate 1 (IRS1), phospholipase C␥, and SHC proteins in fibroblast cells (40) (41) (42) . It is possible that Golgiassociated FIG-ROS signal transduction pathways are similar those of membrane-bound ROS. Conversely, FIG-ROS's association with the Golgi apparatus may also result in a completely unique and different signaling pathway emanating from Golgispecific proteins.
Understanding transformation by FIG-ROS and the signaling systems necessary for this event may have broader implications for the perception of oncogenic processes. Cytogenetic events such as the chromosomal deletion described here may be frequent contributors to oncogenesis in solid tumors. However, the identification of chromosomal events that lead to fusion proteins may have been restricted primarily to hematological malignancies to date because of the technical difficulties associated with carrying out careful karyotypic analysis in solid tumors and the view that translocations, inversions, and deletions were not of major importance in such tumors. The results presented here suggest not only that such events may be contributory to oncogenesis in solid tumors but also that novel mechanisms for creating oncogenic fusion proteins may occur in such tumors. Because receptor tyrosine kinases are promising targets for therapeutic interventions, the identification and characterization of events such as the one described here represent a valuable approach to the development of novel and effective pharmacological strategies for the therapeutic management of solid tumors.
